Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PCRX

PCRX - Pacira BioSciences Inc Stock Price, Fair Value and News

$20.40+0.55 (+2.77%)
Market Closed

45/100

PCRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

45/100

PCRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$19.14

Target 3M

$20.28

Target 6M

$19.88

PCRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PCRX Price Action

Last 7 days

0.8%

Last 30 days

-21.7%

Last 90 days

-4.1%

Trailing 12 Months

-20.8%

PCRX RSI Chart

PCRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PCRX Valuation

Market Cap

877.6M

Price/Earnings (Trailing)

40.94

Price/Sales (Trailing)

1.26

EV/EBITDA

7.46

Price/Free Cashflow

7.07

PCRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$19.14

Target 3M

$20.28

Target 6M

$19.88

PCRX Fundamentals

PCRX Revenue

Revenue (TTM)

698.1M

Rev. Growth (Yr)

6.49%

Rev. Growth (Qtr)

-0.87%

PCRX Earnings

Earnings (TTM)

21.4M

Earnings Growth (Yr)

103.79%

Earnings Growth (Qtr)

212.07%

PCRX Profitability

Operating Margin

78.61%

EBT Margin

5.99%

Return on Equity

2.95%

Return on Assets

1.65%

Free Cashflow Yield

14.15%

PCRX Investor Care

Buy Backs (1Y)

6.83%

Diluted EPS (TTM)

0.48

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025682.6M696.6M698.1M0
2024681.8M690.3M695.0M0
2023669.2M669.2M665.7M675.0M
2022580.5M614.3M654.1M666.8M
2021443.0M503.1M513.3M541.5M
2020435.4M408.3M421.1M429.6M
2019354.0M372.5M393.7M421.0M
2018292.0M305.1M321.2M337.3M
2017280.2M281.5M280.5M286.6M
2016256.2M266.6M272.8M276.4M
2015355.2M367.2M377.3M249.0M
2014110.6M140.7M169.4M333.5M
201342.9M47.7M62.4M85.6M
201219.6M28.3M32.9M39.1M
201113.6M14.2M13.6M15.7M
20100014.7M14.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About Pacira BioSciences Inc

PCRX
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
 CEO
 WEBSITEpacira.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES715

Pacira BioSciences Inc Frequently Asked Questions

PCRX is the stock ticker symbol of Pacira BioSciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Pacira BioSciences Inc is 877.63 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check PCRX's fair value in chart for subscribers.

The fair value guage provides a quick view whether PCRX is over valued or under valued. Whether Pacira BioSciences Inc is cheap or expensive depends on the assumptions which impact Pacira BioSciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PCRX.

As of Wed Jan 28 2026, PCRX's PE ratio (Price to Earnings) is 40.94 and Price to Sales (PS) ratio is 1.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PCRX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Pacira BioSciences Inc has provided -0.101 (multiply by 100 for percentage) rate of return.